KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
Novel Therapies net revenues declined by 21.3% primarily driven by a milestone completion for a collaboration agreement in the prior year period.
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024.
Recent Highlights
- First quarter 2024 net revenues of $8.2 million, an 11% increase over the prior year and record high quarterly revenues
- Core business (U.S. and International) growth of 14% over the prior year, driven by overall SCIg market growth, share gains, and geographic expansion
- Entered a Novel Therapies collaboration with an oncology drug therapy, bringing total collaborations to 16, with 3 signed year-to-date
- Gross profit of $5.1 million, a 23% increase over the prior year, and gross margin of 62%, reflecting year-over-year improvement of 620 basis points
- Ending cash balance of $10.8 million and quarterly cash usage of $0.7 million driven by increased operating leverage and working capital improvements
- Reaffirmed full year 2024 revenue guidance of $31.2 million to $32.2 million, representing growth of 10% to 13% over the prior year.
“We are excited by a strong start to the year, with double-digit record revenue growth in our Core business and the addition of a new oncology collaboration in our Novel Therapies business,” said Linda Tharby, KORU Medical’s President and CEO. “The Core business saw another quarter of sequential growth in the subcutaneous immunoglobulin market, increasing prefill adoption rates, and further geographic expansion. As a part of our Novel Therapies strategy to expand the Freedom subcutaneous infusion system to new drug therapies, we are proud of the progress we’ve made in diversifying our drug pipeline and signing three new collaborations year-to-date. We also continued to drive operating leverage evidenced this quarter by gross margin expansion and a significant reduction in cash usage over the prior year. We are committed to our strategic growth agenda and providing increased value to our customers, patients, and shareholders.”
2024 First Quarter Financial Results
|
|
|
Three Months Ended March 31, |
|
Change from Prior Year |
|
% of Net Revenues |
|
|||||||||||||
|
|
|
2024 |
|
2023 |
|
$ |
% |
|
2024 |
|
2023 |
|
||||||||
|
Net Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Domestic Core |
|
$ |
5,953,865 |
|
$ |
5,719,135 |
|
$ |
234,730 |
|
4.1 |
% |
|
72.7 |
% |
|
77.4 |
% |
|
|
|
International Core |
|
|
1,790,483 |
|
|
1,097,490 |
|
|
692,993 |
|
63.1 |
% |
|
21.8 |
% |
|
14.8 |
% |
|
|
|
Total Core |
|
|
7,744,348 |
|
|
6,816,625 |
|
|
927,723 |
|
13.6 |
% |
|
94.5 |
% |
|
92.2 |
% |
|
|
|
Novel Therapies |
|
|
453,450 |
|
|
575,980 |
|
|
(122,530 |
) |
(21.3 |
%) |
5.5 |
% |
|
7.8 |
% |
|
||
|
Total |
|
$ |
8,197,798 |
|
$ |
7,392,605 |
|
$ |
805,193 |
|
10.9 |
% |
|
100 |
% |
|
100 |
% |
|
|
Total net revenues increased $0.8 million, or 10.9%, to $8.2 million for the three months ended March 31, 2024, as compared with the same period in 2023. Domestic Core revenues increased by 4.1% from higher consumable volumes driven by new patients starts and share gains. International Core revenues increased by 63.1%, from higher consumable and pump volumes driven largely by increased Ig supply, increased penetration within approved indications, and geographic expansion. International orders were expedited for certain distribution partners of $0.26 million in March 2024 to ensure adequate inventory to fulfill patient needs in the event of a supply disruption related to the BSI regulatory review process. Novel Therapies net revenues declined by 21.3% primarily driven by a milestone completion for a collaboration agreement in the prior year period.
Gross profit increased $1.0 million, or 23%, to $5.1 million in the three months ended March 31, 2024, compared to $4.1 million in the same period in 2023. Gross margin increased to 62.3% compared to 56.1% in the first quarter of 2023. The increase in gross margin was primarily driven by production efficiencies from outsourced manufacturing and consolidation of US manufacturing sites.
Total operating expenses for the first quarter of 2024 were $7.1 million, a decrease of $0.1 million, or 1.9%, compared to $7.2 million in the prior year period.
Net loss for the first quarter of 2024 was $1.9 million, or $(0.04) per diluted share, compared to a net loss of $2.4 million, or ($0.05) per diluted share, for the same period of 2023. Adjusted EBITDA for the first quarter of 2024 was ($0.9) million, or ($0.02) per diluted share, compared to adjusted EBITDA of ($2.0) million, or ($0.04) per diluted share, for the same period of 2023. A reconciliation of adjusted EBITDA and adjusted diluted EPS is provided at the end of this press release.
Cash and cash equivalents were $10.8 million as of March 31, 2024, reflecting cash usage of $0.7 million in the first quarter of 2024.
2024 Guidance
Reaffirming full year 2024 net revenue between $31.2 and $32.2 million, representing growth of 10% to 13%
- Gross margin between 59% and 61% for the full year 2024
- 2024 year-end cash balance greater than $8.0 million
- Cash flow breakeven in the fourth quarter of 2024 and cash flow positive for full year 2025
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Wednesday, May 1, 2024 at 4:30 PM ET.
To participate in the call, please dial (877) 407-0784 (domestic) or (201) 689-8560 (international). The live webcast will be available on the IR Calendar on the News/Events page of the Investors section of KORU Medical's website.
Non-GAAP Measures
This press release includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS" and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. Reconciliations of the Company's non-GAAP measures are included at the end of this press release.
About KORU Medical Systems
KORU Medical develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (“the FREEDOM System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements, including, but not limited to, financial guidance and expected operating performance for fiscal 2024. Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forward-looking statements can be identified by words such as "guidance", "expect", "plan", "believe" and "will". Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with SCIg market growth, prefilled syringe penetration, plasma supply, clinical trial activity and success, the Company’s EU certification, the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, global health crises, innovation and competition, labor and supply price increases, inflationary impacts, labor supply, and those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 , which is on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of May 1, 2024. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
|
KORU MEDICAL SYSTEMS, INC. BALANCE SHEETS (UNAUDITED) |
||||||||
|
|
|
|
|
|||||
|
|
|
March 31, |
December 31, |
|||||
|
|
|
2024 |
2023 |
|||||
|
|
|
|
|
|
|
|||
|
ASSETS |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
CURRENT ASSETS |
|
|
|
|
|
|||
|
Cash and cash equivalents |
|
$ |
10,820,317 |
|
$ |
11,482,240 |
|
|
|
Accounts receivable less allowance for doubtful accounts of $24,777 as of March 31, 2024 and $24,777 as of December 31, 2023 |
|
|
4,392,511 |
|
|
4,045,211 |
|
|
|
Inventory |
|
|
3,147,312 |
|
|
3,481,301 |
|
|
|
Other receivables |
|
|
288,714 |
|
|
28,889 |
|
|
|
Prepaid expenses |
|
|
830,408 |
|
|
1,218,288 |
|
|
|
TOTAL CURRENT ASSETS |
|
|
19,479,262 |
|
|
20,255,929 |
|
|
|
Property and equipment, net |
|
|
3,755,530 |
|
|
3,837,657 |
|
|
|
Intangible assets, net of accumulated amortization of $406,801 and $390,341 as of March 31, 2024 and December 31, 2023, respectively |
|
|
737,901 |
|
|
754,361 |
|
|
|
Operating lease right-of-use assets |
|
|
3,428,885 |
|
|
3,514,055 |
|
|
|
Deferred income tax assets, net of allowance for non-realization of deferred tax assets of $6,391,452 and $6,002,777 for March 31, 2024 and December 31, 2023, respectively |
|
|
— |
|
|
— |
|
|
|
Other assets |
|
|
98,970 |
|
|
98,970 |
|
|
|
TOTAL ASSETS |
|
$ |
27,500,548 |
|
$ |
28,460,972 |
|
|
|
|
|
|
|
|
|
|||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
CURRENT LIABILITIES |
|
|
|
|
|
|||
|
Accounts payable |
|
$ |
1,774,185 |
|
$ |
975,193 |
|
|
|
Accrued expenses |
|
|
1,459,405 |
|
|
1,711,427 |
|
|
|
Note payable |
|
|
159,031 |
|
|
314,344 |
|
|
|
Other liabilities |
|
|
457,653 |
|
|
512,520 |
|
|
|
Accrued payroll and related taxes |
|
|
519,441 |
|
|
462,941 |
|
|
|
Financing lease liability – current |
|
|
111,103 |
|
|
109,540 |
|
|
|
Operating lease liability – current |
|
|
372,109 |
|
|
368,313 |
|
|
|
TOTAL CURRENT LIABILITIES |
|
|
4,852,927 |
|
|
4,454,278 |
|
|
|
Financing lease liability, net of current portion |
|
|
288,253 |
|
|
316,623 |
|
|
|
Operating lease liability, net of current portion |
|
|
3,241,837 |
|
|
3,336,300 |
|
|
|
TOTAL LIABILITIES |
|
|
8,383,017 |
|
|
8,107,201 |
|
|
|
|
|
|
|
|
|
|||
|
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|||
|
Common stock, $0.01 par value, 75,000,000 shares authorized, 49,143,589 and 49,089,864 shares issued 45,723,087 and 45,669,362 shares outstanding as of March 31, 2024, and December 31, 2023, respectively |
|
|
491,436 |
|
|
490,899 |
|
|
|
Additional paid-in capital |
|
|
47,717,888 |
|
|
47,018,707 |
|
|
|
Treasury stock, 3,420,502 shares as of March 31, 2024 and December 31, 2023, at cost |
|
|
(3,843,562 |
) |
|
(3,843,562 |
) |
|
|
Accumulated deficit |
|
|
(25,248,231 |
) |
|
(23,312,273 |
) |
|
|
TOTAL STOCKHOLDERS’ EQUITY |
|
|
19,117,531 |
|
|
20,353,771 |
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
27,500,548 |
|
$ |
28,460,972 |
|
|
|
The accompanying notes are an integral part of these financial statements. |
||||||||
|
KORU MEDICAL SYSTEMS, INC. STATEMENTS OF OPERATIONS (UNAUDITED) |
||||||||
|
|
|
|
||||||
|
|
Three Months Ended |
|||||||
|
|
March 31, |
|||||||
|
2024 |
2023 |
|||||||
|
|
|
|
||||||
|
NET REVENUES |
$ |
8,197,798 |
|
$ |
7,392,605 |
|
||
|
Cost of goods sold |
|
3,094,500 |
|
|
3,245,570 |
|
||
|
Gross Profit |
|
5,103,298 |
|
|
4,147,035 |
|
||
|
|
|
|
||||||
|
OPERATING EXPENSES |
|
|
||||||
|
Selling, general and administrative |
|
5,357,620 |
|
|
5,425,877 |
|
||
|
Research and development |
|
1,475,674 |
|
|
1,564,869 |
|
||
|
Depreciation and amortization |
|
231,370 |
|
|
213,117 |
|
||
|
Total Operating Expenses |
|
7,064,664 |
|
|
7,203,863 |
|
||
|
|
|
|
||||||
|
Net Operating Loss |
|
(1,961,366 |
) |
|
(3,056,828 |
) |
||
|
|
|
|
||||||
|
Non-Operating Income/(Expense) |
|
|
||||||
|
Loss on currency exchange |
|
(11,479 |
) |
|
(680 |
) |
||
|
Loss on disposal of fixed assets, net |
|
(300 |
) |
|
(56,279 |
) |
||
|
Interest income, net |
|
37,187 |
|
|
125,502 |
|
||
|
TOTAL OTHER INCOME |
|
25,408 |
|
|
68,543 |
|
||
|
|
|
|
||||||
|
LOSS BEFORE INCOME TAXES |
|
(1,935,958 |
) |
|
(2,988,285 |
) |
||
|
|
|
|
||||||
|
Income Tax Benefit |
|
— |
|
|
577,400 |
|
||
|
|
|
|
||||||
|
NET LOSS |
$ |
(1,935,958 |
) |
$ |
(2,410,885 |
) |
||
|
|
|
|
||||||
|
NET LOSS PER SHARE |
|
|
||||||
|
|
|
|
||||||
|
Basic |
$ |
(0.04 |
) |
$ |
(0.05 |
) |
||
|
Diluted |
$ |
(0.04 |
) |
$ |
(0.05 |
) |
||
|
|
|
|
||||||
|
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING |
|
|
||||||
|
|
|
|
||||||
|
Basic |
|
45,712,224 |
|
|
45,487,593 |
|
||
|
Diluted |
|
45,712,224 |
|
|
45,487,593 |
|
||
|
The accompanying notes are an integral part of these financial statements. |
||||||||
|
KORU MEDICAL SYSTEMS, INC. STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||||||
|
|
|
|
|
|
||||
|
|
|
For the |
||||||
|
|
|
March 31, |
||||||
|
|
|
2024 |
2023 |
|||||
|
|
|
|
|
|
|
|||
|
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|||
|
Net Loss |
|
$ |
(1,935,958 |
) |
$ |
(2,410,885 |
) |
|
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|||
|
Stock-based compensation expense and warrant expense |
|
|
699,718 |
|
|
881,222 |
|
|
|
Depreciation and amortization |
|
|
231,370 |
|
|
213,117 |
|
|
|
Deferred income taxes |
|
|
— |
|
|
(577,400 |
) |
|
|
Loss on disposal of fixed assets |
|
|
300 |
|
|
56,279 |
|
|
|
ROU landlord credit |
|
|
(5,497 |
) |
|
(5,497 |
) |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|||
|
Increase in Accounts receivable |
|
|
(607,125 |
) |
|
(647,994 |
) |
|
|
Decrease / (Increase) in Inventory |
|
|
333,989 |
|
|
(233,551 |
) |
|
|
Decrease in Prepaid expenses and other assets |
|
|
387,880 |
|
|
288,786 |
|
|
|
(Decrease) / Increase in Other liabilities |
|
|
(54,867 |
) |
|
4,207 |
|
|
|
Increase / (Decrease) in Accounts payable |
|
|
798,992 |
|
|
(888,679 |
) |
|
|
Increase / (Decrease) in Accrued payroll and related taxes |
|
|
56,500 |
|
|
(41,984 |
) |
|
|
Decrease in Accrued expenses |
|
|
(252,022 |
) |
|
(1,298,204 |
) |
|
|
NET CASH USED IN OPERATING ACTIVITIES |
|
|
(346,720 |
) |
|
(4,660,583 |
) |
|
|
|
|
|
|
|
|
|||
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|||
|
Purchases of property and equipment |
|
|
(133,083 |
) |
|
(272,605 |
) |
|
|
Purchases of intangible assets |
|
|
(0 |
) |
|
(11,232 |
) |
|
|
NET CASH USED IN INVESTING ACTIVITIES |
|
|
(133,083 |
) |
|
(283,837 |
) |
|
|
|
|
|
|
|
|
|||
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|||
|
Payments on indebtedness |
|
|
(155,313 |
) |
|
(214,892 |
) |
|
|
Payments on finance lease liability |
|
|
(26,807 |
) |
|
(24,080 |
) |
|
|
NET CASH (USED IN) FINANCING ACTIVITIES |
|
|
(182,120 |
) |
|
(238,972 |
) |
|
|
|
|
|
|
|
|
|||
|
NET DECREASE IN CASH AND CASH EQUIVALENTS |
|
|
(661,923 |
) |
|
(5,183,392 |
) |
|
|
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
|
|
11,482,240 |
|
|
17,408,257 |
|
|
|
CASH AND CASH EQUIVALENTS, END OF PERIOD |
|
$ |
10,820,317 |
|
$ |
12,224,865 |
|
|
|
|
|
|
|
|
|
|||
|
Supplemental Information |
|
|
|
|
|
|||
|
Cash paid during the periods for: |
|
|
|
|
|
|||
|
Interest |
|
$ |
12,296 |
|
$ |
12,326 |
|
|
|
Income taxes |
|
$ |
— |
|
$ |
— |
|
|
|
|
|
|
|
|
|
|||
|
Schedule of Non-Cash Operating, Investing and Financing Activities: |
|
|
|
|
|
|||
|
Issuance of common stock as compensation |
|
$ |
123,804 |
|
$ |
175,776 |
|
|
|
The accompanying notes are an integral part of these financial statements. |
|||||||
|
KORU MEDICAL SYSTEMS, INC. SUPPLEMENTAL INFORMATION (UNAUDITED) |
|||||||
|
A reconciliation of our non-GAAP measures is below: |
|||||||
|
|
|
|
|
||||
|
|
Three Months Ended |
||||||
|
Reconciliation of GAAP Net Loss |
March 31, |
||||||
|
to Non-GAAP Adjusted EBITDA: |
2024 |
2023 |
|||||
|
GAAP Net Loss |
$ |
(1,935,958 |
) |
$ |
(2,410,885 |
) |
|
|
Tax (Benefit)/Expense |
|
(388,675 |
) |
|
(577,400 |
) |
|
|
Valuation Allowance for DTA |
|
388,675 |
|
|
— |
|
|
|
Depreciation and Amortization |
|
231,369 |
|
|
213,117 |
|
|
|
Interest (Income), Net |
|
(37,187 |
) |
|
(125,502 |
) |
|
|
Reorganization Charges |
|
99,329 |
|
|
— |
|
|
|
Manufacturing Initiative Expenses |
|
— |
|
|
49,053 |
|
|
|
Product Discontinuance |
|
— |
|
|
— |
|
|
|
Stock-based Compensation Expense |
|
699,718 |
|
|
881,222 |
|
|
|
Adjusted EBITDA |
$ |
(942,729 |
) |
$ |
(1,970,395 |
) |
|
|
Weighted average number common shares |
45,712,224 |
|
45,487,593 |
|
|||
|
|
Three Months Ended |
||||||
|
Reconciliation of Reported Diluted EPS |
March 31, |
||||||
|
to Non-GAAP Adjusted Diluted EPS: |
2024 |
2023 |
|||||
|
Reported Diluted Earnings Per Share |
$ |
(0.04 |
) |
$ |
(0.05 |
) |
|
|
Tax (Benefit)/Expense |
|
(0.01 |
) |
|
(0.01 |
) |
|
|
Valuation Allowance for DTA |
|
0.01 |
|
|
— |
|
|
|
Depreciation and Amortization |
|
0.01 |
|
|
0.01 |
|
|
|
Interest (Income)/Expense, Net |
|
— |
|
|
— |
|
|
|
Reorganization Charges |
|
— |
|
|
— |
|
|
|
Manufacturing Initiative Expenses |
|
— |
|
|
— |
|
|
|
Product Discontinuance |
|
— |
|
|
— |
|
|
|
Stock-based Compensation Expense |
|
0.02 |
|
|
0.02 |
|
|
|
Adjusted Diluted Earnings Per Share |
$ |
(0.02 |
) |
$ |
(0.04 |
) |
|
*Numbers presented are rounded to the nearest whole cent and percentage
Reorganization Charges. We have excluded the effect of reorganization charges in calculating our non-GAAP measures. In 2023 and 2024 we incurred severance expenses related to the reorganization of the leadership team, which we would not have otherwise incurred in periods presented as part of continuing operations.
Manufacturing Initiative Expenses. We have excluded the effect of expenses related to creating manufacturing efficiencies in calculating our non-GAAP measures. We incurred expenses in connection with these initiatives which we would not have otherwise incurred in periods presented as part of our continuing operations.
Stock-based Compensation Expense. We have excluded the effect of stock-based compensation expense in calculating our non-GAAP measures. We record non-cash compensation expenses related to grants of options and restricted shares for executives, employees and consultants, and grants of shares to our board of directors. Depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but will recur in future periods.
Allowance for nonrealization of deferred tax assets (DTA). We have excluded the effect of recording a full valuation allowance on our deferred tax assets in the first quarter ended 2024 in the amount of $0.4 million. It was determined that no valuation allowance was necessary in the first quarter ended 2023.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501464191/en/